High-potency rabies vaccine completes Phase III clinical trials
January 15, 2026
Source: drugdu
67
On January 15, Aim Vaccine (06660) issued an announcement stating that its iterative process high-titer human diploid rabies vaccine has successfully completed Phase III clinical field work.
This product demonstrated high levels of protective antibodies in animal trials, with a significantly higher potency than existing human diploid rabies vaccines. Compared to traditional first-generation human diploid rabies vaccines, the company's vaccine has overcome technical bottlenecks such as low viral titer and low yield, optimized purification processes, and significantly improved product quality and safety.
According to Frost & Sullivan, China's rabies vaccine market is projected to reach RMB 14.8 billion by 2030. This vaccine offers flexible administration methods and has the capacity for large-scale production, making it expected to become the preferred choice for vaccination institutions, further solidifying the company's market position and promoting sustainable development.
https://finance.eastmoney.com/a/202601153619836997.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- 1.2 Billion Yuan! Sino Biopharm Acquires Another Pharmaceutical Company January 15, 2026
- Breakthrough! Changshan Pharmaceutical’s enoxaparin sodium injection receives FDA approval in the United States, marking a new chapter in its overseas market journey! January 15, 2026
- Kelun and Grand Pharmaceuticals compete for the first generic version of a blockbuster heart failure drug! January 15, 2026
- Xuesaitong soft capsules are the company’s exclusive core dosage form January 15, 2026
- Hualan Biological’s investee company’s application for marketing authorization of adalimumab injection has been accepted January 15, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
